Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Allergic bronchopulmonary aspergillosis in cystic fibrosis

G. Mastella, M. Rainisio, H.K. Harms, M.E. Hodson, C. Koch, J. Navarro, B. Strandvik, S.G. McKenzie
European Respiratory Journal 2001 17: 1052-1053; DOI: 10.1183/09031936.01.17510520
G. Mastella
1Cystic Fibrosis Center, Verona, Italy, 2Statistics for Research SFR, Basel, Switzerland, 3Children's Hospital, Munich University, Germany, 4Cystic Fibrosis Dept, Brompton National Hearth & Lung Hospital, London, UK, 5Dept Paediatrics, Rigshospitalet, University Hospital, Copenhagen, Denmark, 6Dept Gastroenterology, R. Debré Hospital, Paris, France, 7Dept Pediatrics, Göteborg University, Göteborg, Sweden and 8Pharmaceutical Division F. Hoffman – La Roche Ltd, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Rainisio
1Cystic Fibrosis Center, Verona, Italy, 2Statistics for Research SFR, Basel, Switzerland, 3Children's Hospital, Munich University, Germany, 4Cystic Fibrosis Dept, Brompton National Hearth & Lung Hospital, London, UK, 5Dept Paediatrics, Rigshospitalet, University Hospital, Copenhagen, Denmark, 6Dept Gastroenterology, R. Debré Hospital, Paris, France, 7Dept Pediatrics, Göteborg University, Göteborg, Sweden and 8Pharmaceutical Division F. Hoffman – La Roche Ltd, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H.K. Harms
1Cystic Fibrosis Center, Verona, Italy, 2Statistics for Research SFR, Basel, Switzerland, 3Children's Hospital, Munich University, Germany, 4Cystic Fibrosis Dept, Brompton National Hearth & Lung Hospital, London, UK, 5Dept Paediatrics, Rigshospitalet, University Hospital, Copenhagen, Denmark, 6Dept Gastroenterology, R. Debré Hospital, Paris, France, 7Dept Pediatrics, Göteborg University, Göteborg, Sweden and 8Pharmaceutical Division F. Hoffman – La Roche Ltd, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M.E. Hodson
1Cystic Fibrosis Center, Verona, Italy, 2Statistics for Research SFR, Basel, Switzerland, 3Children's Hospital, Munich University, Germany, 4Cystic Fibrosis Dept, Brompton National Hearth & Lung Hospital, London, UK, 5Dept Paediatrics, Rigshospitalet, University Hospital, Copenhagen, Denmark, 6Dept Gastroenterology, R. Debré Hospital, Paris, France, 7Dept Pediatrics, Göteborg University, Göteborg, Sweden and 8Pharmaceutical Division F. Hoffman – La Roche Ltd, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Koch
1Cystic Fibrosis Center, Verona, Italy, 2Statistics for Research SFR, Basel, Switzerland, 3Children's Hospital, Munich University, Germany, 4Cystic Fibrosis Dept, Brompton National Hearth & Lung Hospital, London, UK, 5Dept Paediatrics, Rigshospitalet, University Hospital, Copenhagen, Denmark, 6Dept Gastroenterology, R. Debré Hospital, Paris, France, 7Dept Pediatrics, Göteborg University, Göteborg, Sweden and 8Pharmaceutical Division F. Hoffman – La Roche Ltd, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Navarro
1Cystic Fibrosis Center, Verona, Italy, 2Statistics for Research SFR, Basel, Switzerland, 3Children's Hospital, Munich University, Germany, 4Cystic Fibrosis Dept, Brompton National Hearth & Lung Hospital, London, UK, 5Dept Paediatrics, Rigshospitalet, University Hospital, Copenhagen, Denmark, 6Dept Gastroenterology, R. Debré Hospital, Paris, France, 7Dept Pediatrics, Göteborg University, Göteborg, Sweden and 8Pharmaceutical Division F. Hoffman – La Roche Ltd, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Strandvik
1Cystic Fibrosis Center, Verona, Italy, 2Statistics for Research SFR, Basel, Switzerland, 3Children's Hospital, Munich University, Germany, 4Cystic Fibrosis Dept, Brompton National Hearth & Lung Hospital, London, UK, 5Dept Paediatrics, Rigshospitalet, University Hospital, Copenhagen, Denmark, 6Dept Gastroenterology, R. Debré Hospital, Paris, France, 7Dept Pediatrics, Göteborg University, Göteborg, Sweden and 8Pharmaceutical Division F. Hoffman – La Roche Ltd, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S.G. McKenzie
1Cystic Fibrosis Center, Verona, Italy, 2Statistics for Research SFR, Basel, Switzerland, 3Children's Hospital, Munich University, Germany, 4Cystic Fibrosis Dept, Brompton National Hearth & Lung Hospital, London, UK, 5Dept Paediatrics, Rigshospitalet, University Hospital, Copenhagen, Denmark, 6Dept Gastroenterology, R. Debré Hospital, Paris, France, 7Dept Pediatrics, Göteborg University, Göteborg, Sweden and 8Pharmaceutical Division F. Hoffman – La Roche Ltd, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editor:

The main criticism arising from Kastelik et al. 1 on the study of allergic bronchopulmonary aspergillosis (ABPA) based on the data of the European Registry of Cystic Fibrosis (ERCF) 2 regards the criteria adopted for the ABPA diagnosis: positive markers of hypersensitivity to Aspergillus fumigatus plus a physician's suspicion that the patient has ABPA. We agree that the clinical suspicion is subject to some diagnostic inaccuracy. However, the ERCF required that the clinical suspicion was based to some extent on “reversible bronchoconstriction, pulmonary infiltrations, elevated serum immunoglobulin (Ig)-E and/or IgG specific for A. fumigatus, peripheral eosinophilia (>1000 mL−1), recovery of A. fumigatus from sputum or hyphae present on smear, and response to steroids”.

The true problem for the ABPA diagnosis in cystic fibrosis (CF) is that ABPA shares many clinical characteristics with poorly controlled CF lung disease, which makes the recognition of this entity very difficult 3, 4.

Airway obstruction/wheezing, fleeting pulmonary infiltrates and central bronchiectasis, which are still the three classical clinical findings required for the ABPA diagnosis in non-CF patients 5, are really very common in CF patients. Conversely, this difficulty was met in any publication concerning this issue in CF, also in the most recent ones, in which ABPA patients are characterized only on the basis of immunological markers 6–8.

We believe that a clear hypersensitivity to A. fumigatus, combined with a significant rise in the total serum IgE level and the presence of some clinical markers of disease, particularly if they are refractory to antibiotics and regress after corticosteroid therapy, is at the moment the most acceptable compromise for an epidemiological study to be carried out on a large CF population, in which the large number of patients tends to compensate for both overestimation and underestimation of diagnosis. Even a recent study by Nepomuceno et al. 9, using similar criteria to our study, showed a comparable ABPA prevalence in CF of 9%.

The future of ABPA diagnosis in CF relies perhaps on some serological markers which are still under study 10, 11. Both Ig subclasses specific for A. fumigatus 7, 8 and serum or skin IgE which bind to some A. fumigatus allergens, rAspf2, rAspf4 and rAspf6 10, 11, are promising specific markers for ABPA disease. However, these markers once again have to be faced with the difficulty of characterizing exactly the patients with ABPA before being accurately validated as disease-specific.

In our study, it was not possible to present separately the immunological data, with and without clinical suspicion of ABPA, as they were not collated separately.

As regards the role of ABPA in disease progression, our study has shown that the decline in lung function of CF patients with ABPA is not more rapid than that observed in patients without ABPA, even if the ABPA patients presented on average at the enrollment a lower forced expiratory volume in one second value compared to the non-ABPA subjects. There is a strong suspicion that ABPA affects, as a rule, patients already clinically compromised: worse lung function and nutritional status, more bacterial colonization and more antibiotic treatment. However, a real understanding of the true role of ABPA on the disease progression should be based on prospective longitudinal studies of large cohorts of CF patients. This is not possible, even with the best intentions, through a wide CF registry supported by more than 200 CF centres.

However, we believe that the allergic bronchopulmonary aspergillosis information, derived from the European Registry of Cystic Fibrosis database, has given, yet with some approximation, a panoramic view of allergic bronchopulmonary aspergillosis in European cystic fibrosis patients, which could stimulate both an improved attention to detect this complication by cystic fibrosis physicians and further clinical and biological studies aimed to better define the true nature of this complication and its true influence on the course of cystic fibrosis lung disease.

  • © ERS Journals Ltd

References

  1. ↵
    Kastelik JA, Aziz I, Redington AE, Morice AH. Allergic bronchopulmonary aspergillosis in cystic fibrosis. Eur Respir J 2001;17:156.
    OpenUrlFREE Full Text
  2. ↵
    Mastella G, Rainisio M, Harms HK, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A european epidemiological study. Eur Respir J 2000;16:464–471.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Milla CE. Allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol 1999;27:71–73.
    OpenUrlPubMedWeb of Science
  4. ↵
    Geller DE, Kaplowitz H, Light MJ, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. Reported prevalence, regional distribution and patients characteristics. Chest 1999;116:639–646.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    Patterson R, Greenberger PA, Harris KE. Allergic bronchopulmonary aspergillosis. Chest 2000;118:7–9.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Skov M, Poulsen LK, Koch Ch. Increased antigen-specific Th-2 response in allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis. Pediatr Pulmonol 1999;27:74–79.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Skov M, Pressler T, Jensen HE, et al. Specific IgG subclass antibody patterns to Aspergillus fumigatus in patients with cystic fibrosis with allergic bronchopulmonary aspergillosis. Thorax 1999;54:44–50.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Skov M, Koch Ch, Reinert CM, Poulsen LK. Diagnosis of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis. Allergy 2000;55:50–58.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Nepomuceno IB, Erig S, Moss RB. Allergic bronchopulmonary aspergillosis in cystic fibrosis. Role of atopy and response to Itraconazole. Chest 1999;115:364–370.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    Hemmann S, Menz G, Ismail Ch, et al. Skin test reactivity to 2 recombinant Aspergillus fumigatus allergens in A. fumigatus-sensitized asthmatic subjects allows diagnostic separation of allergic bronchopulmonary aspergillosis from fungal sensitization. J Allergy Clin Immunol 1999;104:601–607.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    Kurup UP, Banerjee B, Hemmann S, et al. Selected recombinant Aspergillus fumigatus allergens bind specifically to IgE in ABPA. Clin Exper Allergy 2000;30:988–993.
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 17 Issue 5 Table of Contents
  • Table of Contents
  • Index by author
  • Podcast
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Allergic bronchopulmonary aspergillosis in cystic fibrosis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Allergic bronchopulmonary aspergillosis in cystic fibrosis
G. Mastella, M. Rainisio, H.K. Harms, M.E. Hodson, C. Koch, J. Navarro, B. Strandvik, S.G. McKenzie
European Respiratory Journal May 2001, 17 (5) 1052-1053; DOI: 10.1183/09031936.01.17510520

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Allergic bronchopulmonary aspergillosis in cystic fibrosis
G. Mastella, M. Rainisio, H.K. Harms, M.E. Hodson, C. Koch, J. Navarro, B. Strandvik, S.G. McKenzie
European Respiratory Journal May 2001, 17 (5) 1052-1053; DOI: 10.1183/09031936.01.17510520
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • References
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Clinical outcomes of bronchiectasis in India
  • Reply: Clinical outcomes of bronchiectasis in India
  • Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society